CDR Update

CDR Update is an e-bulletin to keep people who are interested in CDR informed of program initiatives and activities, including opportunities to provide input.

You may subscribe or unsubscribe to CDR Update at any time.

What is this?



  1. CDR Update - Issue 8

    December 18, 2003

    In This Issue

    • Submission Status
    • Christmas and New Year’s Holiday Schedule
    • Communications Officer Leaving CDR Directorate

    View Report

  2. CDR Update - Issue 7

    November 19, 2003

    In This Issue

    • Amendments to the Common Drug Review Submission Guidelines for Manufacturers
    • Canadian Expert Drug Advisory Committee
    • Barb Shea Appointed Vice-President of CDR
    • Stan Bardal Joins CDR Directorate as Pharmacist

    View Report

  3. CDR Update - Issue 6

    September 17, 2003

    In This Issue

    • Correction to Appendix 1 of the Submission Guidelines for Manufacturers
    • CDR Welcomes Advance Notification of Submissions
    • Role of the Common Drug Review Committee
    • Christmas and New Year’s Holiday Schedule

    View Report

  4. CDR Update - Issue 5

    September 5, 2003

    In This Issue

    • CEDAC Members Appointed
    • CEDAC members are:

    View Report

  5. CDR Update - Issue 4

    August 22, 2003

    In This Issue

    • June 25th CDR Directorate Workshop on "Preparing Submissions for the CDR"
    • Revised CDR Submission Guidelines for Manufacturers
    • Updated CDR FAQs
    • Timeline Update
    • Request for notification of submissions
    • New CDRC Chair

    View Report

  6. CDR Update - Issue 3

    June 20, 2003

    In This Issue

    • CDR Documents Now Available
    • Still Time fo Register for June 25 Workshop
    • Transition Update

    View Report

  7. CDR Update - Issue 2

    May 29, 2003

    In This Issue

    • Workshop On Preparing Submissions For The Common Drug Review

    View Report

  8. CDR Update - Issue 1

    May 1, 2003

    In This Issue

    • Transition to the Permanent Common Drug Review
    • The Common Drug Review
    • Objectives of the Common Drug Review
    • Interim Common Drug Review
    • Transition to the Permanent Common Drug Review
    • Transparency and Communications
    • Frequently Asked Questions
    • Who's Who at the CDR Directorate

    View Report